Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
198.10M | 189.27M | 174.02M | 165.54M | 75.58M | 71.49M | Gross Profit |
171.02M | 162.20M | 148.44M | 142.37M | 70.20M | 66.97M | EBIT |
22.31M | 19.73M | 19.23M | 18.13M | 13.24M | 19.21M | EBITDA |
36.65M | 54.26M | 51.60M | 47.54M | 18.48M | 24.06M | Net Income Common Stockholders |
14.88M | 11.70M | 9.23M | 9.41M | 12.90M | 16.84M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
72.16M | 34.59M | 78.54M | 47.16M | 235.62M | 47.85M | Total Assets |
565.96M | 543.65M | 576.98M | 568.79M | 311.60M | 115.76M | Total Debt |
35.89M | 40.15M | 86.69M | 113.08M | 1.15M | 2.02M | Net Debt |
-36.27M | 5.56M | 8.15M | 65.93M | -234.47M | -45.83M | Total Liabilities |
236.84M | 215.06M | 249.13M | 235.77M | 51.32M | 47.36M | Stockholders Equity |
329.12M | 328.59M | 327.84M | 333.02M | 260.28M | 68.39M |
Cash Flow | Free Cash Flow | ||||
68.61M | 24.91M | 83.20M | 12.93M | 13.21M | 10.96M | Operating Cash Flow |
69.53M | 41.86M | 98.75M | 26.96M | 23.54M | 20.67M | Investing Cash Flow |
-14.27M | -15.81M | -15.34M | -307.32M | -10.32M | -9.71M | Financing Cash Flow |
-46.99M | -70.00M | -53.28M | 91.90M | 174.55M | -10.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | £840.96M | 33.17 | 3.41% | 1.10% | 11.20% | -6.80% | |
72 Outperform | £461.60M | 64.65 | 2.93% | 1.14% | 40.66% | -55.09% | |
69 Neutral | £721.40M | 61.82 | 4.50% | 1.43% | 6.74% | 54.83% | |
65 Neutral | £333.86M | 8.54 | 11.74% | ― | 38.80% | ― | |
61 Neutral | £1.15B | ― | -23.77% | ― | 7.97% | 12.94% | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% |
Craneware plc has announced that Bain Capital Private Equity is assessing a possible offer for the company. While no formal proposal has been received, Bain Capital has until June 13, 2025, to announce its intentions. This potential offer could significantly impact Craneware’s market positioning and stakeholder interests, pending further developments.
The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.
Craneware plc has announced a change in its major holdings, with Liontrust Investment Partners LLP adjusting its voting rights in the company. The adjustment reflects a decrease in Liontrust’s total voting rights from 10.977% to 10.1601%, indicating a strategic shift in their investment stance. This change may impact the company’s shareholder dynamics and influence future corporate decisions.
Craneware plc announced that its Chair, Will Whitehorn, purchased 1,911 Ordinary Shares, reflecting a minor increase in his stake in the company. This transaction highlights confidence in Craneware’s market position and could positively influence stakeholder perception. Additionally, the company adjusted its total voting rights following the transfer of shares to satisfy employee share options, which now stands at 35,409,802 shares with voting rights.
Craneware plc, a prominent provider of healthcare financial performance solutions, announced details regarding its interim dividend payment. Shareholders who opted for the US dollar payment will receive their dividends at an exchange rate of $1.30. This announcement reflects Craneware’s commitment to providing flexible financial options to its shareholders, potentially impacting its market positioning by enhancing shareholder satisfaction.
Craneware plc has reported record interim financial results for the first half of FY25, with a notable return to double-digit growth rates. The company’s revenue exceeded $100 million, driven by expansion with existing customers and new customer acquisitions. The strong financial performance is underpinned by high levels of annual recurring revenue and customer retention. Craneware’s strategic partnership with Microsoft has led to significant advancements in AI-enhanced offerings, including the launch of Trisus® Assist, an AI-powered personal assistant. The company continues to invest in R&D and innovation, strengthening its market position and supporting its ambitious growth strategy. The outlook remains positive, with expectations of sustained demand from US hospitals focusing on strategic growth post-election.